Shares in Novocure (NSDQ:NVCR) jumped nearly 50% today after the company touted 5-year data today from the Phase III pivotal EF-14 trial evaluating its Optune device with temozolomide chemotherapy for the treatment of newly-diagnosed glioblastoma.

Data from 695 patients show a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, the St. Helier, N.J.-based company said. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication

Get the full story at our sister site, Drug Delivery Business News.